WO2006025378A1 - 高脂血症治療剤 - Google Patents
高脂血症治療剤 Download PDFInfo
- Publication number
- WO2006025378A1 WO2006025378A1 PCT/JP2005/015756 JP2005015756W WO2006025378A1 WO 2006025378 A1 WO2006025378 A1 WO 2006025378A1 JP 2005015756 W JP2005015756 W JP 2005015756W WO 2006025378 A1 WO2006025378 A1 WO 2006025378A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pitapastatin
- ezetimibe
- salt
- hyperlipidemia
- present
- Prior art date
Links
- 201000005577 familial hyperlipidemia Diseases 0.000 title abstract 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 12
- OLNTVTPDXPETLC-XPWALMASSA-N ezetimibe Chemical compound N1([C@@H]([C@H](C1=O)CC[C@H](O)C=1C=CC(F)=CC=1)C=1C=CC(O)=CC=1)C1=CC=C(F)C=C1 OLNTVTPDXPETLC-XPWALMASSA-N 0.000 claims description 37
- 229960000815 ezetimibe Drugs 0.000 claims description 37
- 239000003814 drug Substances 0.000 claims description 25
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 17
- 229940124597 therapeutic agent Drugs 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 3
- VGYFMXBACGZSIL-MCBHFWOFSA-N pitavastatin Chemical compound OC(=O)C[C@H](O)C[C@H](O)\C=C\C1=C(C2CC2)N=C2C=CC=CC2=C1C1=CC=C(F)C=C1 VGYFMXBACGZSIL-MCBHFWOFSA-N 0.000 abstract description 5
- -1 pitavastatine lactone Chemical class 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 60
- 239000008280 blood Substances 0.000 description 28
- 210000004369 blood Anatomy 0.000 description 28
- 159000000007 calcium salts Chemical class 0.000 description 15
- 230000000694 effects Effects 0.000 description 14
- 229940079593 drug Drugs 0.000 description 12
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 6
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical class CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 239000000654 additive Substances 0.000 description 4
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000700198 Cavia Species 0.000 description 3
- 229960002797 pitavastatin Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 2
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 description 2
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 2
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000003524 antilipemic agent Substances 0.000 description 2
- 229960005370 atorvastatin Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- CABVTRNMFUVUDM-VRHQGPGLSA-N (3S)-3-hydroxy-3-methylglutaryl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C[C@@](O)(CC(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 CABVTRNMFUVUDM-VRHQGPGLSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N beta-monoglyceryl stearate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229960002965 pravastatin Drugs 0.000 description 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 235000020374 simple syrup Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000004328 sodium tetraborate Substances 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a therapeutic agent for hyperlipidemia that exhibits an excellent lowering effect on blood cholesterol.
- Hyperlipidemia is a symptom in which lipoproteins in the blood are abnormally increased, and particularly in blood cholesterol. Hyperlipidemia has been confirmed to be strongly related to diseases such as arteriosclerosis and myocardial infarction, and its treatment is considered to be extremely important.
- HMG-CoA reductase such as oral nostatin, sympastatin, pravastatin, funolepastatin, atorvastatin, rosnostatin, pitapastatin, etc.
- Inhibitors are central to the treatment.
- pitapastatin ((3R, 5S, 6E) — 7— [2 cyclopropyl 4- (4-fluorophenol) 3-quinolyl] — 3,5-dihydroxy-6-heptenoic acid) is a strong HMG—CoA It is known that it has a reductase inhibitory action and is useful as a therapeutic agent for hyperlipidemia! / Patent Documents 1-3.
- HMG-CoA reductase inhibitor When an HMG-CoA reductase inhibitor is administered to hyperlipidemic patients, blood cholesterol decreases. However, in many patients with very high blood cholesterol levels, HMG-CoA reductase inhibitors often do not reduce blood cholesterol levels sufficiently. In that case, the method of increasing the dose of HMG-CoA reductase inhibitor and treating it is recommended due to safety issues, etc.
- ezetimibe ((3R, 43) -1- (4-Fonoleferrofe-nore) -3— [(33) -3— (4 fluorophenol) 3 hydroxypropyl] —4— (4 hydroxyphenol) 2) 2-azetidinone) is an antihyperlipidemic agent that suppresses the absorption of diet-derived and bile acid-derived cholesterol in the intestinal tract and lowers blood cholesterol through a mechanism different from that of HMG-CoA reductase inhibitors. It is known that there is (Patent Document 4).
- Non-patent Document 4 It has been disclosed that the combined use of an HMG-CoA reductase inhibitor and ezetimibe is effective in reducing blood cholesterol and treating atherosclerosis. In addition, a blood cholesterol lowering effect by the combined use of an HMG-CoA reductase inhibitor and ezetimibe has also been reported (Non-patent Document 1).
- Patent Document 1 Japanese Patent No. 2569746
- Patent Document 2 US Pat. No. 5,102,888
- Patent Document 3 European Patent No. 304063
- Patent Document 4 WO95Z08532 pamphlet
- An object of the present invention is to provide a therapeutic agent for hyperlipidemia and a therapeutic agent for hypercholesterolemia that are excellent in blood cholesterol lowering action. Means for solving the problem
- the present inventors have found that when pitapastatin and ezetimibe are used in combination, the blood cholesterol lowering action is remarkably excellent, and hyperlipidemia and hypercholesterolemia The present invention was completed by finding that it is useful for the treatment of symptom.
- the present invention provides a therapeutic agent for hyperlipidemia characterized by containing ezetimibe and pitapastatin, a salt of pitapastatin, or a latataton form of pitapastatin.
- the present invention provides a therapeutic agent for hypercholesterolemia characterized by comprising ezetimibe and pitapastatin, a salt of pitapastatin or a latataton form of pitavastatin.
- the present invention also provides use of ezetimibe and pitapastatin, a salt of pitapastatin, or a latataton form of pitapastatin for the manufacture of a therapeutic agent for hyperlipidemia.
- the present invention also provides ezetimibe and pita for producing a therapeutic agent for hypercholesterolemia. It provides the use of a patinatin, a salt of pitanostatin or a ratataton form of pitapastatin.
- the present invention provides a method for treating hyperlipidemia, characterized by administering an effective amount of ezetimibe and pitapastatin, a salt of pitapastatin or a latataton form of pitavastatin.
- the present invention provides a method for treating hypercholesterolemia, characterized by administering an effective amount of ezetimibe and pitapastatin, a salt of pitapastatin or a latataton form of pitavastatin.
- the therapeutic agent for hyperlipidemia and therapeutic agent for hypercholesterolemia of the present invention is excellent in the action of lowering blood cholesterol and is effective in treating hyperlipidemia and hypercholesterolemia.
- FIG. 1 is a graph showing the blood cholesterol-lowering effect of co-administration of pitapastatin calcium salt and ezetimibe.
- FIG. 2 is a graph showing a blood cholesterol reduction effect by the combined administration of atorvastatin calcium salt and ezetimibe.
- pitapastatin a salt of pitapastatin or a latataton form of pitapastatin (hereinafter sometimes referred to as pitapastatins) used in the present invention has cholesterol synthesis inhibitory activity based on inhibition of HMG-CoA reductase. It is known as a drug for treating hyperlipidemia.
- pitapastatin salts are preferred, and calcium salts and sodium salts are particularly preferred.
- Ezetimibe used in the present invention is known to be a drug that exhibits an effect by suppressing absorption of cholesterol in the intestine.
- the present invention treats pitapastatins and ezetimibe in combination.
- pitapastatins and ezetimibe were each administered alone in an evaluation system using guinea pigs. Compared to cases, the combined administration of both drugs has the effect of significantly reducing blood cholesterol.
- the administration form of pitapastatins and ezetimibe in the present invention can be selected as appropriate.
- these administration forms such as powders, granules, dry syrups, tablets, capsules, injections, etc., are pitanostatins.
- a pharmaceutically acceptable carrier can be blended with ezetimibe and can be produced by a conventional pharmaceutical method known to those skilled in the art.
- a binder, a disintegrant, a lubricant, a coloring agent, a corrigent, a flavoring agent, etc. a tablet, Granules, powders, capsules, etc.
- a binder, a disintegrant, a lubricant, a coloring agent, a corrigent, a flavoring agent, etc. a tablet, Granules, powders, capsules, etc.
- excipients include lactose, sodium chloride salt, glucose, starch, microcrystalline cellulose, and silicic acid.
- Binders include water, ethanol, propanol, simple syrup, gelatin solution, hydroxypropenoresenorelose, methinoresenorelose, ethinolecellulose, shellac, calcium phosphate, polybulurpyrrolidone, etc., and disintegrants agar powder, sodium bicarbonate , Sodium lauryl sulfate, stearic acid monoglyceride, etc., refined talc, stearate, borax, polyethylene glycol, etc. as lubricants, j8-carotene, yellow ferric oxide, carmela etc. as colorants, Examples thereof include sucrose and orange peel.
- oral liquids, syrups, elixirs and the like can be produced by adding a flavoring agent, a buffering agent, a stabilizer, a preservative and the like by a conventional method.
- a flavoring agent e.g., peppermint, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, kaolin, sorbiol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, sorbitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol, mannitol
- a pH adjuster, a stabilizer, an isotonic agent and the like can be added, and subcutaneous, intramuscular and intravenous injections can be produced by conventional methods.
- additives include those commonly used in the field, such as sodium phosphate as a pH regulator, sodium pyrosulfite as a stabilizer, and isotonic agent.
- salt include sodium salt.
- the mode of use of the drug of the present invention is not particularly limited, and may be administered separately at intervals other than simultaneously administering both drugs.
- pitapastatins and ezetimibe can be used as a set of both drugs in a single formulation or separately. May be.
- both preparations should not have the same dosage form.
- the dose of the drug of the present invention is appropriately selected depending on the symptoms, but pitanostatins are 0.1 to 50 mg per day, preferably 1 to 20 mg, and ezetimibe is 0.1 to 500 mg per day. 1 to: LOOmg should be administered. The administration may be once a day, but may be divided into two or more times.
- the blood cholesterol lowering effect when pitapastatin calcium salt and ezetimibe were administered in combination was measured by the following test method.
- the same method was used when atornostatin calcium salt was administered in combination instead of pitapastatin calcium.
- a 6-week-old Hartley male guinea pig (Japan SLC Co., Ltd.) was used. Throughout the experiment period, the light-dark cycle (bright period due to room light: 7:00 am to 7:00 pm), kept in a breeding room maintained at a temperature of 23 ⁇ 3 ° C and a humidity of 55 ⁇ 15%, solid feed (RC — 4: Oriental Yeast Industry Co., Ltd.) and tap water were given freely.
- the present invention Pitapastatin calcium salt and ezetimibe are suspended in a 0.5% by mass aqueous solution of sodium carboxymethyl cellulose (Iwai Chemicals Co., Ltd.), pitapastatin strength lucum salt is lmg / mL, ezetimibe is 3mg / mL was prepared. Since pitabastatin calcium salt contains 9.43% by mass of water, it was corrected by weighing 1.1 times the dose. The suspension was stored refrigerated (4 ° C) in a light-shielding bottle, and preparation was performed every 7 days. Comparative example: Atorvastatin calcium salt is used in place of pitapastatin calcium salt Similarly, a comparative test preparation was produced.
- the present invention 24 guinea pigs were divided into the following 4 groups (6 cases in each group): control group, pitabastatin calcium salt alone (lmgZkg) group, ezetimibe alone (3 mg / kg) group and combination group (pitapastatin calcium salt ( lmgZkg) and ezetimibe (3 mgZkg)) were grouped so that the blood total cholesterol and blood triglyceride values were averaged. Both drugs, respectively once daily LmLZkg administered 14-day repeated oral, the control group was orally administered the sodium carboxymethyl cellulose 0.5 mass 0/0 solution (lmLZkg). In both groups, blood was collected after fasting for 18 hours from the final administration, and blood cholesterol levels were measured.
- Comparative Example Using 24 guinea pigs, the test was carried out in the same manner as in the present invention except that pitapastatin calcium salt was replaced with atorvastatin calcium salt.
- the dosage of atorvastatin calcium salt was 5 mgZkg for both the atorvastati calcium salt group and the atorvastati calcium salt and ezetimibe combination group.
- a multigroup comparison between the control group and the drug-administered group was performed using Bartlett's analysis of variance Dunnett's multiple comparison test, and a risk rate of less than 5% was determined to be significant.
- the reduction rate (%) is (((average value of total cholesterol in control group) and (average value of total cholesterol in each group) Z average value of total cholesterol in control group) X 100), and relative index is ((each) Average blood group total cholesterol (Z control group total blood cholesterol average value).
- the blood cholesterol lowering effect was significantly enhanced compared to the group administered with each drug alone (p ⁇ 0. 001).
- the combined administration of the pitapastatin calcium salt of the present invention and ezetimibe is more conspicuous than the combined administration of other HMG-CoA reductase inhibitors and ezetimibe.
- C has a lowering effect on blood cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2005800291311A CN101010080B (zh) | 2004-08-31 | 2005-08-30 | 高脂血症治疗剂 |
ES05777087T ES2354366T3 (es) | 2004-08-31 | 2005-08-30 | Medicamento para la hiperlipemia. |
AT05777087T ATE489093T1 (de) | 2004-08-31 | 2005-08-30 | Heilmittel für hyperlipidämie |
KR1020077001596A KR101244508B1 (ko) | 2004-08-31 | 2005-08-30 | 고지혈증 치료제 |
JP2006532716A JP4886516B2 (ja) | 2004-08-31 | 2005-08-30 | 高脂血症治療剤 |
DE602005024981T DE602005024981D1 (de) | 2004-08-31 | 2005-08-30 | Heilmittel für hyperlipidämie |
PL05777087T PL1785137T3 (pl) | 2004-08-31 | 2005-08-30 | Środek do leczenia hiperlipemii |
EP05777087A EP1785137B1 (en) | 2004-08-31 | 2005-08-30 | Remedy for hyperlipemia |
HK08100666.5A HK1110200A1 (en) | 2004-08-31 | 2008-01-18 | Remedy for hyperlipemia |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US60552504P | 2004-08-31 | 2004-08-31 | |
US60/605,525 | 2004-08-31 | ||
US10/997,878 | 2004-11-29 | ||
US10/997,878 US20060046996A1 (en) | 2004-08-31 | 2004-11-29 | Method for treating hyperlipidemia |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006025378A1 true WO2006025378A1 (ja) | 2006-03-09 |
Family
ID=35944235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/015756 WO2006025378A1 (ja) | 2004-08-31 | 2005-08-30 | 高脂血症治療剤 |
Country Status (13)
Country | Link |
---|---|
US (2) | US20060046996A1 (ja) |
EP (1) | EP1785137B1 (ja) |
JP (1) | JP4886516B2 (ja) |
KR (1) | KR101244508B1 (ja) |
CN (1) | CN101010080B (ja) |
AT (1) | ATE489093T1 (ja) |
CY (1) | CY1111150T1 (ja) |
DE (1) | DE602005024981D1 (ja) |
ES (1) | ES2354366T3 (ja) |
HK (1) | HK1110200A1 (ja) |
PL (1) | PL1785137T3 (ja) |
PT (1) | PT1785137E (ja) |
WO (1) | WO2006025378A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019043880A (ja) * | 2017-09-01 | 2019-03-22 | 興和株式会社 | 医薬組成物 |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0215579D0 (en) * | 2002-07-05 | 2002-08-14 | Astrazeneca Ab | Chemical compounds |
US20060276486A1 (en) * | 2003-04-17 | 2006-12-07 | Kowa Co., Ktd. | Lklf/klf2 gene expression promoter |
US7871998B2 (en) * | 2003-12-23 | 2011-01-18 | Astrazeneca Ab | Diphenylazetidinone derivatives possessing cholesterol absorption inhibitory activity |
GB0329778D0 (en) * | 2003-12-23 | 2004-01-28 | Astrazeneca Ab | Chemical compounds |
TW200619204A (en) * | 2004-12-10 | 2006-06-16 | Kowa Co | Method for reduction, stabilization and prevention of rupture of lipid rich plaque |
UY29607A1 (es) * | 2005-06-20 | 2007-01-31 | Astrazeneca Ab | Compuestos quimicos |
MY148538A (en) * | 2005-06-22 | 2013-04-30 | Astrazeneca Ab | Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions |
SA06270191B1 (ar) * | 2005-06-22 | 2010-03-29 | استرازينيكا ايه بي | مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم |
AR054482A1 (es) * | 2005-06-22 | 2007-06-27 | Astrazeneca Ab | Derivados de azetidinona para el tratamiento de hiperlipidemias |
AR057383A1 (es) * | 2005-06-22 | 2007-12-05 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto |
AR057380A1 (es) * | 2005-06-22 | 2007-11-28 | Astrazeneca Ab | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos |
TW200811098A (en) * | 2006-04-27 | 2008-03-01 | Astrazeneca Ab | Chemical compounds |
UA108742C2 (uk) | 2009-09-23 | 2015-06-10 | Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1 | |
US20130023513A1 (en) * | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
TWI586380B (zh) * | 2013-12-18 | 2017-06-11 | 夢製藥公司 | 包含HMG-CoA還原酶抑制劑及膽固醇吸收抑制劑之醫藥組合製劑 |
US10413543B2 (en) * | 2015-09-01 | 2019-09-17 | Sun Pharma Advanced Research Company Ltd. | Stable multiparticulate pharmaceutical composition of rosuvastatin |
JPWO2020178878A1 (ja) * | 2019-03-01 | 2020-09-10 | ||
US11833133B2 (en) * | 2020-08-13 | 2023-12-05 | Orient Pharma Co., Ltd. | Solid oral pharmaceutical composition |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505141A (ja) * | 1992-12-23 | 1996-06-04 | シェリング・コーポレーション | コレステロール生合成阻害剤およびβ−ラクタムコレステロール吸収阻害剤の組合せ |
WO2004010993A1 (en) * | 2002-07-26 | 2004-02-05 | Merck Sharp & Dohme Limited | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5854259A (en) * | 1987-08-20 | 1998-12-29 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones |
JP2569746B2 (ja) * | 1987-08-20 | 1997-01-08 | 日産化学工業株式会社 | キノリン系メバロノラクトン類 |
US5185328A (en) * | 1987-08-20 | 1993-02-09 | Nissan Chemical Industries Ltd. | Quinoline type mevalonolactones useful for treating hyperlipidemia, hyperlipoproteinemia or atherosclerosis |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US6465477B1 (en) * | 1997-08-18 | 2002-10-15 | Kowa Company, Ltd. | Stable pharmaceutical composition |
US7148197B2 (en) * | 2000-08-24 | 2006-12-12 | The Regents Of The University Of California | Orally administered small peptides synergize statin activity |
US6777552B2 (en) * | 2001-08-16 | 2004-08-17 | Teva Pharmaceutical Industries, Ltd. | Processes for preparing calcium salt forms of statins |
ES2377526T3 (es) * | 2005-01-10 | 2012-03-28 | Cortendo Ab (Publ) | 2S,4R ketoconazol para el tratamiento de la diabetes, el síndrome metabólico y otras afecciones |
-
2004
- 2004-11-29 US US10/997,878 patent/US20060046996A1/en not_active Abandoned
-
2005
- 2005-08-30 ES ES05777087T patent/ES2354366T3/es active Active
- 2005-08-30 AT AT05777087T patent/ATE489093T1/de active
- 2005-08-30 CN CN2005800291311A patent/CN101010080B/zh active Active
- 2005-08-30 WO PCT/JP2005/015756 patent/WO2006025378A1/ja active Application Filing
- 2005-08-30 KR KR1020077001596A patent/KR101244508B1/ko active IP Right Review Request
- 2005-08-30 EP EP05777087A patent/EP1785137B1/en not_active Revoked
- 2005-08-30 JP JP2006532716A patent/JP4886516B2/ja active Active
- 2005-08-30 DE DE602005024981T patent/DE602005024981D1/de active Active
- 2005-08-30 PT PT05777087T patent/PT1785137E/pt unknown
- 2005-08-30 PL PL05777087T patent/PL1785137T3/pl unknown
-
2006
- 2006-10-12 US US11/546,248 patent/US7459447B2/en active Active
-
2008
- 2008-01-18 HK HK08100666.5A patent/HK1110200A1/xx not_active IP Right Cessation
-
2011
- 2011-02-01 CY CY20111100106T patent/CY1111150T1/el unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08505141A (ja) * | 1992-12-23 | 1996-06-04 | シェリング・コーポレーション | コレステロール生合成阻害剤およびβ−ラクタムコレステロール吸収阻害剤の組合せ |
WO2004010993A1 (en) * | 2002-07-26 | 2004-02-05 | Merck Sharp & Dohme Limited | Composition comprising a cholesterol absorption inhibitor, an hmg-coa reductase inhibitor and a stabilizing agent |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019043880A (ja) * | 2017-09-01 | 2019-03-22 | 興和株式会社 | 医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
JP4886516B2 (ja) | 2012-02-29 |
US20060046996A1 (en) | 2006-03-02 |
JPWO2006025378A1 (ja) | 2008-05-08 |
US7459447B2 (en) | 2008-12-02 |
HK1110200A1 (en) | 2008-07-11 |
PT1785137E (pt) | 2010-12-23 |
CY1111150T1 (el) | 2015-06-11 |
KR20070047766A (ko) | 2007-05-07 |
EP1785137A1 (en) | 2007-05-16 |
EP1785137A4 (en) | 2007-12-19 |
DE602005024981D1 (de) | 2011-01-05 |
EP1785137B1 (en) | 2010-11-24 |
ES2354366T3 (es) | 2011-03-14 |
PL1785137T3 (pl) | 2011-04-29 |
US20070032467A1 (en) | 2007-02-08 |
CN101010080A (zh) | 2007-08-01 |
ATE489093T1 (de) | 2010-12-15 |
KR101244508B1 (ko) | 2013-03-18 |
CN101010080B (zh) | 2011-02-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006025378A1 (ja) | 高脂血症治療剤 | |
KR101420319B1 (ko) | 고지혈증 예방 및/또는 치료제 | |
EA030093B1 (ru) | Лекарственная форма пирфенидона в виде капсул с фармацевтически приемлемыми эксципиентами | |
NO336891B1 (no) | Farmasøytiske sammensetninger av CETP inhibitorer | |
KR20210136081A (ko) | 화합물의 제제 및 그의 용도 | |
KR101390144B1 (ko) | 염증성 장질환 치료제 | |
CN116832164A (zh) | 包含etc1002及他汀类药物的固定剂量组合 | |
KR20080085208A (ko) | 당뇨병 치료를 위한 트리아진 유도체 및 hmg-coa리덕타제 저해제의 조합물 | |
CN1148190C (zh) | 用于免疫调节的药物组合物 | |
JPH07504890A (ja) | Nmda拮抗剤の相乗効果 | |
KR101436644B1 (ko) | 당뇨병 치료제 | |
WO2006011495A1 (ja) | 高コレステロール血症及び/又は高トリグリセリド血症治療剤 | |
JP6227535B2 (ja) | 脂質異常症の予防又は治療薬 | |
JP2007513991A (ja) | メタボリック症候群の処置のためのスタチンの使用 | |
US20090233898A1 (en) | Pharmaceutical Compositions Comprising Simvastatin and Ezetimibe | |
KR20180104744A (ko) | 중증 신장 기능 장애를 갖는 암 환자에 대한 치료 방법 | |
WO2005117853A1 (ja) | 高脂血症治療剤及び糖尿病治療剤 | |
JP2005089300A (ja) | 高脂血症治療剤 | |
JP5330825B2 (ja) | トリグリセリド低下剤及び高インスリン血症改善剤 | |
WO2023225300A2 (en) | Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto | |
CN114377136A (zh) | 用于高脂血症治疗的联合用药物及其用途 | |
BG1302U1 (bg) | Лекарствена форма на глимепирид | |
WO2018092085A1 (ru) | Фармацевтическая композиция для лечения туберкулеза |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006532716 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077001596 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005777087 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580029131.1 Country of ref document: CN |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWP | Wipo information: published in national office |
Ref document number: 2005777087 Country of ref document: EP |